Cargando…
Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer
PURPOSE OF REVIEW: Compensatory mechanisms leading to increased androgen receptor expression and activity after androgen ablation or anti-androgen treatment have been identified in prostate cancer. After hydroxyflutamide and bicalutamide were used in therapy of prostate cancer over many years, novel...
Autor principal: | Culig, Zoran |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700216/ https://www.ncbi.nlm.nih.gov/pubmed/29214142 http://dx.doi.org/10.1007/s40610-017-0079-1 |
Ejemplares similares
-
Epigenetic Regulation in Prostate Cancer Progression
por: Ruggero, Katia, et al.
Publicado: (2018) -
The Role of the Calcitonin Peptide Family in Prostate Cancer and Bone Metastasis
por: Warrington, Jessica Isabel, et al.
Publicado: (2017) -
Store-Operated Ca(2+) Entry as a Prostate Cancer Biomarker — a Riddle with Perspectives
por: Kappel, Sven, et al.
Publicado: (2017) -
Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial
por: Izumi, Kouji, et al.
Publicado: (2022) -
A Prospective Study of the Relationship Between Clinical Outcomes After Enzalutamide and Serum Androgen Levels Measured via Liquid Chromatography-tandem Mass Spectrometry in Patients with Castration-resistant Prostate Cancer
por: Miyazawa, Yoshiyuki, et al.
Publicado: (2021)